Welcome to our dedicated page for KalVista Pharmaceuticals news (Ticker: KALV), a resource for investors and traders seeking the latest updates and insights on KalVista Pharmaceuticals stock.
KalVista Pharmaceuticals, Inc. (KALV) is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of small molecule protease inhibitors. The company's mission is to bring innovative treatments to patients suffering from a range of diseases, with a strong focus on hereditary angioedema (HAE) and diabetic macular edema (DME).
KalVista's core business revolves around developing small molecule plasma kallikrein inhibitors. Their product portfolio includes:
- Hereditary Angioedema (HAE) inhibitors: These inhibitors are designed to prevent and treat the debilitating attacks associated with HAE, a disorder characterized by severe swelling in various body parts.
- Diabetic Macular Edema (DME) inhibitors: These inhibitors target plasma kallikrein, which is implicated in the retinal vascular permeability that leads to DME, a common complication of diabetes that can cause vision loss.
The company operates primarily in the United States and has made significant strides in its research and development efforts. Recent achievements include successful clinical trials, strategic partnerships, and securing funding to advance their pipeline projects.
KalVista maintains a robust financial condition, supported by several rounds of funding and strategic investments. The company prioritizes transparency and regularly updates stakeholders on its progress through press releases and public disclosures.
Investors looking to keep abreast of the latest developments and financial performance of KalVista Pharmaceuticals can find comprehensive updates and reports on their official website and through stock market platforms like StockTitan.
KalVista Pharmaceuticals presented data at the 2024 HAEi Global Angioedema Forum showing the effectiveness of sebetralstat in reducing anxiety during hereditary angioedema (HAE) attacks. The data, from the KONFIDENT phase 3 clinical trial, revealed that sebetralstat significantly reduced anxiety compared to placebo, especially in patients with moderate-to-extreme anxiety.
Key findings include:
- Anxiety reduction correlated with earlier symptom relief
- Sebetralstat 300mg and 600mg doses showed significant anxiety reduction versus placebo
- For moderate-to-extreme anxiety, sebetralstat showed greater improvement at 4 and 12 hours compared to placebo
Additional presentations highlighted the impact of HAE attacks on quality of life, work productivity, and the potential benefits of early treatment with oral on-demand therapies.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) has announced the granting of inducement options to six newly-hired employees. These options, totaling 31,000 shares of KalVista common stock, were granted on October 1, 2024, in compliance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $11.39 per share, matching the closing price of KalVista common stock on the grant date.
The vesting schedule for these options includes 25% vesting on the one-year anniversary of the vesting commencement date, with the remaining 75% vesting in equal monthly installments over the following three years. Each option has a 10-year term and is subject to KalVista's Inducement Equity Incentive Plan and a stock option agreement.
KalVista Pharmaceuticals (NASDAQ: KALV) has submitted Marketing Authorization Applications (MAAs) for sebetralstat in the United Kingdom, Switzerland, Australia, and Singapore. Sebetralstat is an investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema (HAE) attacks in adults and adolescents aged 12 and older. The submissions were made through the Access Consortium framework, designed to maximize regulatory collaboration and support timely review.
The MAAs are supported by results from the KONFIDENT phase 3 clinical trial and ongoing KONFIDENT-S open label extension trial. Sebetralstat met its primary endpoint, achieving faster symptom relief than placebo, and demonstrated a consistent safety profile. The KONFIDENT-KID trial for pediatric patients aged 2-11 began dosing ahead of schedule in June 2024.
If approved, sebetralstat would be the first oral on-demand treatment for HAE, addressing a significant unmet need globally.
KalVista Pharmaceuticals (NASDAQ: KALV) announced the acceptance of nine abstracts for poster presentation at the HAEi Global Angioedema Forum (GAF) in Copenhagen, Denmark on October 4-5, 2024. The presentations cover various aspects of Hereditary Angioedema (HAE) and its treatment, including:
1. Impact of oral sebetralstat on anxiety associated with HAE attacks
2. Anxiety associated with parenteral on-demand HAE treatment
3. Conceptual model of patient anxiety and treatment burden during HAE attacks
4. Effects of delayed HAE attack treatment on quality of life and work ability
5. Impact of HAE attacks on patients receiving long-term prophylaxis or on-demand treatment
6. Analysis of European and US patient subgroups in the Phase 3 KONFIDENT trial
7. Patient-reported benefits of early on-demand HAE attack treatment
8. Patient perspectives on future oral on-demand therapies for HAE attacks
9. Global frequency and diagnosis of HAE with normal C1INH
KalVista Pharmaceuticals (NASDAQ: KALV) has announced its participation in the 2024 Cantor Global Healthcare Conference. The company's management will engage in a fireside chat on Thursday, September 19th, 2024 at 10:20 a.m. ET in New York. This event presents an opportunity for investors and stakeholders to gain insights into KalVista's current operations and future plans.
A live webcast of the presentation will be accessible on KalVista's official website. For those unable to attend or watch live, an audio archive will remain available on the company's website for 30 days following the presentation, ensuring widespread access to the information shared during the conference.
KalVista Pharmaceuticals (NASDAQ: KALV) has appointed Brian Piekos as its new Chief Financial Officer. Piekos brings over 25 years of financial and strategic planning experience in the biopharmaceutical industry. He joins KalVista from Elicio Therapeutics, where he served as CFO. The appointment comes as KalVista prepares for the commercialization of sebetralstat, a potential novel therapy for hereditary angioedema.
As part of his employment agreement, Piekos received inducement options to purchase 100,000 shares of KalVista's Common Stock at an exercise price of $11.87 per share. These options will vest over a four-year period, subject to his continued service.
KalVista Pharmaceuticals (NASDAQ: KALV) presented additional analyses of sebetralstat, its investigational oral plasma kallikrein inhibitor for hereditary angioedema (HAE) attacks, at the Bradykinin Symposium 2024. The data from phase 2 and 3 trials, including the KONFIDENT-S open-label extension, demonstrated consistent efficacy and safety profiles across the clinical program.
Key findings include:
- Sebetralstat showed rapid symptom relief and a safety profile comparable to placebo
- Median time to treatment was 9 minutes for all attacks and 8 minutes for laryngeal attacks
- Median time to beginning of symptom relief was 1.8 hours for all attacks and 1.3 hours for laryngeal attacks
The oral administration of sebetralstat may address challenges associated with current injectable treatments, potentially transforming HAE management if approved.
KalVista Pharmaceuticals (NASDAQ: KALV) reported significant progress in Q1 2025 fiscal year. The FDA accepted their New Drug Application for sebetralstat, setting a PDUFA date of June 17, 2025. The EMA also validated their Marketing Authorization Application. KalVista plans to file for approval in the UK, Japan, and other countries later in 2024.
Financial highlights include:
- R&D expenses increased to $26.6 million from $19.3 million year-over-year
- G&A expenses rose to $17.6 million from $9.8 million
- Net loss widened to $40.4 million, or $(0.87) per share
- Cash position decreased to $174.3 million from $210.4 million in April 2024
The company initiated a pediatric clinical trial (KONFIDENT-KID) for sebetralstat and published phase 3 KONFIDENT trial data in the New England Journal of Medicine.
KalVista Pharmaceuticals (NASDAQ: KALV) has granted inducement options to nine newly-hired employees. The options allow for the purchase of a total of 55,000 shares of KalVista common stock at an exercise price of $12.37 per share, matching the closing price on September 3, 2024. These options vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following three years. The grants, made under KalVista's Inducement Equity Incentive Plan, are subject to continued employment and have a 10-year term. This action aligns with Nasdaq Listing Rule 5635(c)(4), which allows for inducement grants to new employees.
KalVista Pharmaceuticals (NASDAQ: KALV) announced FDA acceptance of its New Drug Application (NDA) for sebetralstat, an oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema (HAE) attacks. The FDA set a PDUFA goal date of June 17, 2025. If approved, sebetralstat would be the first oral, on-demand treatment for HAE in patients aged 12 and older.
The NDA is supported by data from the KONFIDENT phase 3 trial and ongoing KONFIDENT-S open label extension trial. Sebetralstat met the primary endpoint, achieving faster symptom relief than placebo and demonstrating a favorable safety profile. The KONFIDENT-KID trial for pediatric patients aged 2-11 years has begun dosing. KalVista has also submitted a Marketing Authorization Application to the European Medicines Agency and plans to file for approval in other countries in 2024.
FAQ
What is the current stock price of KalVista Pharmaceuticals (KALV)?
What is the market cap of KalVista Pharmaceuticals (KALV)?
What does KalVista Pharmaceuticals specialize in?
What diseases does KalVista target with its products?
What is a plasma kallikrein inhibitor?
Where does KalVista Pharmaceuticals operate?
How can investors stay updated on KalVista's progress?
Has KalVista formed any strategic partnerships?
What are KalVista's recent achievements?
What is hereditary angioedema (HAE)?
What is diabetic macular edema (DME)?
What financial condition is KalVista in?
